Anti-VLA4 en es it fr

Anti-VLA4 Brand names, Anti-VLA4 Analogs

Anti-VLA4 Brand Names Mixture

  • No information avaliable

Anti-VLA4 Chemical_Formula

No information avaliable

Anti-VLA4 RX_link

Anti-VLA4 fda sheet

Anti-VLA4 msds (material safety sheet)

Anti-VLA4 Synthesis Reference

Sequence listed in Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997;8(1):3-16

Anti-VLA4 Molecular Weight

No information avaliable

Anti-VLA4 Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Anti-VLA4 H2O Solubility

No information avaliable

Anti-VLA4 State


Anti-VLA4 LogP

No information avaliable

Anti-VLA4 Dosage Forms

Solution (IV Infusion)

Anti-VLA4 Indication

For treatment of multiple sclerosis

Anti-VLA4 Pharmacology

In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain.

Anti-VLA4 Absorption

No information avaliable

Anti-VLA4 side effects and Toxicity

No information avaliable

Anti-VLA4 Patient Information


Anti-VLA4 Organisms Affected

Humans and other mammals